<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Antimalarial drugs were at the forefront of the COVID-19 pandemic based on some early, uncontrolled, and small case series suggesting potential efficacy in the treatment of SARS-CoV-2 infection. Although in vitro data suggest chloroquine and hydroxychloroquine both inhibit coronavirus,
 <xref rid="bib24" ref-type="bibr">
  <sup>24</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib25" ref-type="bibr">
  <sup>25</sup>
 </xref> available clinical data do not suggest any benefit for the treatment of patients critically ill with COVID-19.
 <xref rid="bib26" ref-type="bibr">26</xref>, 
 <xref rid="bib27" ref-type="bibr">27</xref>, 
 <xref rid="bib28" ref-type="bibr">28</xref>, 
 <xref rid="bib29" ref-type="bibr">29</xref>, 
 <xref rid="bib30" ref-type="bibr">30</xref>
</p>
